Skip to main content
Shattuck Labs, Inc. logo

Shattuck Labs, Inc. — Investor Relations & Filings

Ticker · STTK ISIN · US82024L1035 US Manufacturing
Filings indexed 361 across all filing types
Latest filing 2026-05-07 Interim / Quarterly Rep…
Country US United States of America
Listing US STTK

About Shattuck Labs, Inc.

https://www.shattucklabs.com/

Shattuck Labs, Inc. is a biotechnology company that develops biologic medicines for inflammatory and immune-mediated diseases. The company specializes in Tumor Necrosis Factor (TNF) receptor modulators, utilizing its expertise in protein engineering to create novel therapeutics. Its lead program, SL-325, is a potentially first-in-class monoclonal antibody designed as an antagonist of Death Receptor 3 (DR3). This program targets the clinically validated TL1A/DR3 pathway to achieve a deep and durable blockade for the treatment of conditions such as Inflammatory Bowel Disease (IBD) and other inflammatory autoimmune diseases.

Recent filings

Filing Released Lang Actions
10-Q - Shattuck Labs, Inc. (0001680367) (Filer)
Interim / Quarterly Report
2026-05-07 English
8-K - Shattuck Labs, Inc. (0001680367) (Filer)
Regulatory Filings
2026-05-07 English
ARS - Shattuck Labs, Inc. (0001680367) (Filer)
Annual Report
2026-04-08 English
DEF 14A - Shattuck Labs, Inc. (0001680367) (Filer)
Proxy Solicitation & Information Statement
2026-04-08 English
SCHEDULE 13G Filing
Major Shareholding Notification
2026-02-06 English
8-K Filing
Regulatory Filings
2026-02-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.